<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260607069683N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-09-13</date_registration>
      <primary_sponsor>Ahvaz University of Medical Sciences</primary_sponsor>
      <public_title>The effectiveness of implementing clinical guidelines on respiratory function in school-age children</public_title>
      <acronym>TEICGRF</acronym>
      <scientific_title>The effectiveness of implementing clinical guidelines on respiratory function in school-age children with allergic rhinitis</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>72</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/91882</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Other, Purpose: Education/Guidance, Randomization description: Random sampling process and sample size, which will be allocated to two control groups (36 people) and intervention (36 people) based on simple random method. Randomization unit: individual, randomization tool: random number table, to create a random sequence with the help of a random number table and by a statistical consultant, patients were randomly assigned one of the even and odd codes. Patients who were assigned even numbers were placed in the first group and patients with odd codes were placed in the second group.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Allergic rhinitis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: After recording demographic information, patients in the intervention group will undergo a simple educational intervention guide for the care of school-age children with AR based on the EUFOREA guidelines in addition to routine care. The training of this guide will be held for 8 sessions in teaching hospitals affiliated with Ahvaz Jundishapur University of Medical Sciences. The educational sessions will be held in a room in teaching hospitals affiliated with Ahvaz Jundishapur University of Medical Sciences. About 12 children will participate in each session. During this period, patients in the control group will only receive routine care related to the care of children with AR. As explained in the previous sections, the educational intervention protocol based on the EUFOREA clinical guidelines will be held in 8 sessions. The topic of the first session will be familiarization with allergic rhinitis. In the first session, children will be familiarized with the concept of allergic rhinitis, its common symptoms including runny nose, sneezing, itching, and nasal congestion, and its difference from colds or other respiratory diseases. This session will explain the importance of early diagnosis and proper treatment of the disease, the role of genetic and environmental factors, and the impact of untreated rhinitis on a child's academic performance and quality of life. The topic of the second session will be recognizing allergens and effective environmental factors. The second session will focus on recognizing common triggers and allergens such as dust mites, mold, pets, pollen, air pollution, and cigarette smoke. In this session, children will be taught how these factors can aggravate symptoms and what steps can be taken to identify and control them in the living environment. The topic of the third session will be the principles of prevention and avoidance of allergens. The third session will teach practical strategies for reducing exposure to allergens. Emphasis will be placed on things such as properly ventilating the child's room, washing sheets regularly with hot water, using hypoallergenic covers for pillows and mattresses, limiting contact with pets, and using masks during pollen seasons. The topic of the fourth session will be teaching non-pharmacological treatments. During the fourth session, non-pharmacological measures in the control of allergic rhinitis will be taught. Participants will be introduced to the importance of nasal irrigation with saline solution and will be given practical training on how to do it correctly. In this session, how to prepare homemade saline solution and the appropriate frequency of irrigation will be explained. The topic of the fifth session will be drug therapy training based on the EUFOREA guidelines. In this session, children will be taught proper drug therapy. Participants will be introduced to the types of drugs used in allergic rhinitis (antihistamines, corticosteroid sprays, and combination drugs) and the role of each in controlling symptoms. The correct use of nasal spray will be practiced practically. The topic of the sixth session will be introduction to specific immunotherapy. In this session, the concept of immunotherapy and its role in the long-term treatment of allergic rhinitis will be taught. Participants will be introduced to the two main immunotherapy methods (subcutaneous and sublingual), the duration of treatment, its benefits in reducing the severity of symptoms and preventing asthma. The topic of the seventh session will be training in symptom monitoring and self-assessment. The seventh session will focus on promoting self-care. In this session, how to assess symptoms using a visual analog scale (VAS) or Emoji-VAS will be taught so that children can record the severity of their symptoms on a daily or weekly basis. The topic of the eighth session will be review, summary and final evaluation. In the last session, the content of the training of the previous seven sessions will be reviewed and the extent of learning and behavior change of the participants will be assessed. Key points related to prevention, drug therapy, nasal irrigation and allergen avoidance were reviewed again. Immediately after the intervention, the VAS scale and the patient's clinical status form will be collected by the researcher using spirometry. After 30 days, the parameters related to the study objectives will be collected again by the researcher in both the control and intervention groups using the same patient clinical status form using spirometry and visual analog scale (VAS). Intervention 2: Control group: They are not given any training.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is "There is no further information."</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Absalan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ilam Janbazan, end of Sayyad Shirazi Boulevard</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6931174434</zip>
        <telephone>+98 84 3223 1058</telephone>
        <email>absalan.m@ajums.ac</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Absalan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ilam Janbazan, end of Sayyad Shirazi Boulevard</address>
        <city>Ahvaz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6931174434</zip>
        <telephone>+98 84 3223 1058</telephone>
        <email>absalan.m@ajums.ac</email>
        <affiliation>Ahvaz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>School-age children (6 to 12 years old)
Confirmation of the diagnosis of seasonal allergic rhinitis (AR) by a specialist physician based on clinical criteria
Absence of other chronic respiratory diseases such as severe asthma, chronic bronchitis, or active respiratory infections
Obtaining informed consent from the child's parents or legal guardian and, where possible, the child's assent
Children in stable general health, without acute or chronic diseases that could affect the study results</inclusion_criteria>
      <agemin>6 years</agemin>
      <agemax>12 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of hypersensitivity or severe adverse reactions to treatments recommended in the clinical guideline
Unwillingness or inability of the family or child to adhere to study instructions or participate in follow-up sessions
Family or child's refusal to continue participating in the study or unwillingness to provide informed consent.
The presence of severe psychological or behavioral problems in the child that may make it difficult to cooperate in the study.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>J30</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Vasomotor and allergic rhinitis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: After recording demographic information, patients in the intervention group will undergo a simple educational intervention guide for the care of school-age children with AR based on the EUFOREA guidelines in addition to routine care. The training of this guide will be held for 8 sessions in teaching hospitals affiliated with Ahvaz Jundishapur University of Medical Sciences. The educational sessions will be held in a room in teaching hospitals affiliated with Ahvaz Jundishapur University of Medical Sciences. About 12 children will participate in each session. During this period, patients in the control group will only receive routine care related to the care of children with AR. As explained in the previous sections, the educational intervention protocol based on the EUFOREA clinical guidelines will be held in 8 sessions. The topic of the first session will be familiarization with allergic rhinitis. In the first session, children will be familiarized with the concept of allergic rhinitis, its common symptoms including runny nose, sneezing, itching, and nasal congestion, and its difference from colds or other respiratory diseases. This session will explain the importance of early diagnosis and proper treatment of the disease, the role of genetic and environmental factors, and the impact of untreated rhinitis on a child's academic performance and quality of life. The topic of the second session will be recognizing allergens and effective environmental factors. The second session will focus on recognizing common triggers and allergens such as dust mites, mold, pets, pollen, air pollution, and cigarette smoke. In this session, children will be taught how these factors can aggravate symptoms and what steps can be taken to identify and control them in the living environment. The topic of the third session will be the principles of prevention and avoidance of allergens. The third session will teach practical strategies for reducing exposure to allergens. Emphasis will be placed on things such as properly ventilating the child's room, washing sheets regularly with hot water, using hypoallergenic covers for pillows and mattresses, limiting contact with pets, and using masks during pollen seasons. The topic of the fourth session will be teaching non-pharmacological treatments. During the fourth session, non-pharmacological measures in the control of allergic rhinitis will be taught. Participants will be introduced to the importance of nasal irrigation with saline solution and will be given practical training on how to do it correctly. In this session, how to prepare homemade saline solution and the appropriate frequency of irrigation will be explained. The topic of the fifth session will be drug therapy training based on the EUFOREA guidelines. In this session, children will be taught proper drug therapy. Participants will be introduced to the types of drugs used in allergic rhinitis (antihistamines, corticosteroid sprays, and combination drugs) and the role of each in controlling symptoms. The correct use of nasal spray will be practiced practically. The topic of the sixth session will be introduction to specific immunotherapy. In this session, the concept of immunotherapy and its role in the long-term treatment of allergic rhinitis will be taught. Participants will be introduced to the two main immunotherapy methods (subcutaneous and sublingual), the duration of treatment, its benefits in reducing the severity of symptoms and preventing asthma. The topic of the seventh session will be training in symptom monitoring and self-assessment. The seventh session will focus on promoting self-care. In this session, how to assess symptoms using a visual analog scale (VAS) or Emoji-VAS will be taught so that children can record the severity of their symptoms on a daily or weekly basis. The topic of the eighth session will be review, summary and final evaluation. In the last session, the content of the training of the previous seven sessions will be reviewed and the extent of learning and behavior change of the participants will be assessed. Key points related to prevention, drug therapy, nasal irrigation and allergen avoidance were reviewed again. Immediately after the intervention, the VAS scale and the patient's clinical status form will be collected by the researcher using spirometry. After 30 days, the parameters related to the study objectives will be collected again by the researcher in both the control and intervention groups using the same patient clinical status form using spirometry and visual analog scale (VAS).</i_keyword>
      <i_keyword>Control group: They are not given any training.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Forced vital capacity (FVC): The amount of air that can be exhaled from the lungs after the deepest possible breath. Timepoint: Before, immediately and after the intervention. Method of measurement: Pulmonary function assessment using spirometry.</prim_outcome>
      <prim_outcome>Forced expiratory volume in the first second (FVC): The volume of air exhaled in the first second during forced expiration after maximal inspiration. Timepoint: Before, immediately and after the intervention. Method of measurement: Pulmonary function assessment using spirometry.</prim_outcome>
      <prim_outcome>Nasal congestion. Timepoint: Before, immediately and after the intervention. Method of measurement: Based on the VSA scale, a score of zero indicates no nasal congestion, a score of 1 to 3 indicates mild nasal congestion.</prim_outcome>
      <prim_outcome>Nasal congestion. Timepoint: Before, immediately and after the intervention. Method of measurement: Based on the VSA scale, a score of zero indicates no nasal congestion, a score of 1 to 3 indicates mild nasal congestion.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Assessing symptoms of allergic rhinitis. Timepoint: Before, immediately, and after the intervention. Method of measurement: Visual Analogue Scale.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Jondishapour University</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-01-11</approval_date>
        <contact_name>Ethics committee of AHWAZ University of Medical Sciences</contact_name>
        <contact_address>University of Medical Sciences AHWAZ Khouzestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
